Perceptive Advisors Llc Purchases 175,000 Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) Stock

Global Blood Therapeutics Inc (NASDAQ:GBT) major shareholder Perceptive Advisors Llc acquired 175,000 shares of the stock in a transaction dated Tuesday, December 19th. The shares were purchased at an average price of $38.00 per share, for a total transaction of $6,650,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Global Blood Therapeutics Inc (NASDAQ GBT) traded up $0.15 during trading on Friday, reaching $56.60. The company’s stock had a trading volume of 968,595 shares, compared to its average volume of 1,600,000. The firm has a market capitalization of $2,600.00 and a price-to-earnings ratio of -22.20. Global Blood Therapeutics Inc has a one year low of $14.70 and a one year high of $57.75.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period in the prior year, the business earned ($0.58) earnings per share. sell-side analysts anticipate that Global Blood Therapeutics Inc will post -2.54 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Daiwa SB Investments Ltd. lifted its stake in shares of Global Blood Therapeutics by 158.4% during the fourth quarter. Daiwa SB Investments Ltd. now owns 8,676 shares of the company’s stock valued at $341,000 after acquiring an additional 5,318 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Global Blood Therapeutics by 189.5% during the third quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock valued at $62,805,000 after acquiring an additional 1,323,934 shares during the period. Perceptive Advisors LLC lifted its stake in shares of Global Blood Therapeutics by 8.4% during the third quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock valued at $132,399,000 after acquiring an additional 330,139 shares during the period. Orbimed Advisors LLC lifted its stake in shares of Global Blood Therapeutics by 10.2% during the third quarter. Orbimed Advisors LLC now owns 2,393,635 shares of the company’s stock valued at $74,322,000 after acquiring an additional 221,700 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in shares of Global Blood Therapeutics by 43.8% during the third quarter. Janus Henderson Group PLC now owns 1,415,558 shares of the company’s stock valued at $43,953,000 after acquiring an additional 431,325 shares during the period. 85.72% of the stock is currently owned by institutional investors.

A number of analysts have recently issued reports on the company. HC Wainwright set a $73.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Thursday. BidaskClub lowered Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 20th. Wedbush reaffirmed an “outperform” rating and issued a $73.00 price target on shares of Global Blood Therapeutics in a research note on Friday, December 15th. Needham & Company LLC boosted their price target on Global Blood Therapeutics from $51.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. Finally, Oppenheimer set a $79.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $62.07.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/global-blood-therapeutics-inc-gbt-major-shareholder-acquires-6650000-00-in-stock.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply